Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Johnson Controls International PLC (JCI) vs GeneDx Holdings Corp (WGS) Price & Performance

Johnson Controls International PLCTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Johnson Controls International PLC vs GeneDx Holdings Corp — how do they compare? Johnson Controls International PLC trades at $153 (market cap $93.74B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Johnson Controls International PLC is far larger — about 38.4× GeneDx Holdings Corp's market cap, and Johnson Controls International PLC pays a 1.03% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

JCIWGS
Market Cap
$93.74B$2.44B
Sector
IndustrialsTechnology
52-Week High
$154.76$167.51
52-Week Low
$103.52$34.51
Enterprise Value
$102.58B$2.48B
Dividend Yield
1.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Johnson Controls International PLC

JCI trades at $153.59, up 1.92% on the day, with a bullish technical outlook and strong institutional support. Recent Q3 2026 earnings beat expectations with $1.42 EPS versus $1.30 expected, driven by double-digit organic growth in data-center thermal systems. The company raised FY26 guidance, reflecting robust demand and operational momentum. Valuation ratios remain elevated, with a P/E of 43.59 and P/S of 3.82, indicating premium pricing relative to historical norms.

The outlook is positive, supported by earnings momentum and AI-driven demand for cooling solutions, but risks include high valuation sensitivity and debt levels. Analyst consensus price target is $168.25, suggesting ~9.5% upside, with no sell ratings among 45 analysts. Investors should monitor execution on guidance and macroeconomic impacts on construction and HVAC markets.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.

Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.

Returns comparison

Trailing returns across standard periods

About Johnson Controls International PLC

Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.

Read more on JCI

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS